List of Excipients in Branded Drug ELIQUIS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	ANHYDROUS LACTOSE
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	CELLULOSE, MICROCRYSTALLINE
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	CROSCARMELLOSE SODIUM
ER Squibb & Sons LLC	ELIQUIS	apixaban	0003-0893	FERRIC OXIDE YELLOW

Eliquis Excipient Strategy and Commercial Opportunities

Last updated: October 9, 2026

Eliquis, the apixaban brand marketed by Bristol Myers Squibb and Pfizer, is a small-molecule oral anticoagulant with a simple immediate-release tablet platform. Its commercial opportunity is driven less by novel excipient IP than by reliable sourcing, formulation replication, regulatory execution, and manufacturing scale. The core product uses conventional excipients, allowing generic manufacturers and contract development and manufacturing organizations to compete on cost, supply security, dissolution performance, and market access.

U.S. Eliquis tablets contain apixaban at 2.5 mg and 5 mg strengths. The formulation uses lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and a film-coating system based on hypromellose, lactose, titanium dioxide, triacetin, and iron oxides. The product is FDA-approved for stroke and systemic embolism reduction in nonvalvular atrial fibrillation, deep-vein thrombosis and pulmonary embolism treatment, and post-orthopedic-surgery prophylaxis.[1]

What excipients are used in Eliquis tablets?

The Eliquis tablet is an immediate-release, film-coated oral dosage form. The inactive ingredients disclosed in the U.S. prescribing information are:

Formulation component	Eliquis excipient	Primary function
Tablet core	Anhydrous lactose	Diluent and bulk former
Tablet core	Microcrystalline cellulose	Diluent, compression aid, structural matrix
Tablet core	Croscarmellose sodium	Superdisintegrant
Tablet core	Sodium lauryl sulfate	Wetting agent and dissolution aid
Tablet core	Magnesium stearate	Lubricant
Film coat	Hypromellose	Film former
Film coat	Lactose	Coating filler and opacity modifier
Film coat	Titanium dioxide	Opacifier and colorant
Film coat	Triacetin	Plasticizer
Film coat	Iron oxide yellow	Colorant in the 5-mg tablet
Film coat	Iron oxide red	Colorant in the 2.5-mg tablet

The 2.5-mg tablet is pink, while the 5-mg tablet is yellow. Color differentiation supports dose identification and medication-use safety. The formulation is not dependent on a specialized controlled-release polymer, lipid carrier, nanoparticle, or device component.[1]

Which excipients create the greatest technical value?

Croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate have greater process sensitivity than lactose or microcrystalline cellulose.

Croscarmellose sodium affects tablet breakup and can influence early dissolution. Sodium lauryl sulfate improves wetting of the poorly water-soluble active pharmaceutical ingredient, but excessive surfactant can alter powder flow, tablet strength, or dissolution behavior. Magnesium stearate affects lubrication and ejection force, while over-lubrication can reduce tablet tensile strength and slow dissolution.

The commercial value is therefore concentrated in consistent grade selection and process control rather than in exclusivity over the individual excipients.

What formulation strategy is required to replicate Eliquis?

A generic apixaban developer must reproduce the reference product’s critical quality attributes while meeting FDA abbreviated new drug application requirements. The key formulation objectives are:

1. Match the reference product’s immediate-release dissolution profile.
2. Maintain content uniformity at the low 2.5-mg dose.
3. Control particle-size distribution and blend uniformity.
4. Reproduce tablet hardness, friability, disintegration, and coating performance.
5. Demonstrate bioequivalence under the applicable FDA guidance.
6. Maintain stability through the proposed shelf life.

The low drug load creates a blend-uniformity challenge. A 2.5-mg tablet contains a small quantity of apixaban relative to total tablet mass, making segregation, sampling error, and dosing variability important development risks.

How should excipient selection be optimized?

A practical generic formulation strategy is to retain the same excipient classes as Eliquis unless a documented performance or supply reason supports substitution.

Development objective	Preferred excipient strategy
Low-dose uniformity	Use a narrow particle-size distribution for apixaban and a high-uniformity diluent system
Rapid tablet breakup	Optimize croscarmellose sodium level and distribution
Wetting and dissolution	Control sodium lauryl sulfate grade, concentration, and mixing sequence
Robust compression	Use microcrystalline cellulose with predictable compactibility
Lubrication	Minimize magnesium stearate blending time after endpoint
Color matching	Use controlled iron oxide pigment concentration and coating weight
Supply continuity	Qualify at least two sources for high-risk excipients
Regulatory simplicity	Prefer pharmacopeial grades with established pharmaceutical use

Direct substitution can create bioequivalence or dissolution risk even when the excipient name remains unchanged. Lactose particle size, microcrystalline cellulose morphology, croscarmellose swelling capacity, and sodium lauryl sulfate purity can vary across suppliers.

What commercial opportunities exist for Eliquis excipient suppliers?

The largest opportunities are in qualified multi-source supply, high-consistency excipient grades, and formulation-support services.

Excipient supply opportunities

Excipient manufacturers can target:

• Anhydrous lactose for direct compression and low-moisture processing.
• Microcrystalline cellulose grades optimized for low-dose blend uniformity.
• Croscarmellose sodium with controlled swelling and wicking performance.
• Pharmaceutical-grade sodium lauryl sulfate with low impurity profiles.
• Low-peroxide, low-metal magnesium stearate.
• Hypromellose and triacetin systems for rapid, uniform film coating.
• Iron oxide pigments with tight color and particle-size specifications.
• Titanium dioxide alternatives or reformulated coating systems for jurisdictions with tighter scrutiny of titanium dioxide.

The strongest supplier proposition is not simply price. It is documented lot-to-lot consistency, dual sourcing, regulatory support, and validated performance in high-volume tablet operations.

CDMO and development-service opportunities

CDMOs can compete by offering:

• Apixaban formulation development.
• Process development for direct compression or wet granulation.
• Analytical method transfer.
• Dissolution method development.
• Scale-up and process validation.
• ANDA-ready stability packages.
• Commercial tablet compression and film coating.
• Regional packaging and serialization.

A CDMO with existing anticoagulant manufacturing capability can reduce development time and support multiple generic customers. Packaging services also have value because Eliquis is distributed in multiple strengths and market-specific pack configurations.

What patents protect Eliquis and its formulation?

The principal U.S. Eliquis patent estate originated with Bristol Myers Squibb and related research entities. The key compound patent, U.S. Patent No. 6,967,208, covers apixaban and related factor Xa inhibitor chemistry. Its term was extended by pediatric exclusivity beyond the ordinary patent expiration date.[2]

FDA Orange Book listings, rather than the product label, control the operative list of patents submitted by the sponsor for approved Eliquis products. The listed estate has included compound, formulation, and related patent rights. The exact scope and expiration of each listed patent can differ by dosage form, product number, and statutory adjustments.[3]

Are Eliquis excipients themselves strongly protected?

Generally, no. The individual excipients are established pharmaceutical materials with extensive prior art and multiple commercial suppliers. A supplier is unlikely to obtain meaningful market exclusivity merely by selling lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, hypromellose, or iron oxides.

Potential protection can arise from:

• A specific apixaban-excipient composition.
• A narrow excipient concentration range.
• A manufacturing process that improves dissolution or stability.
• A particle-size or coating architecture.
• A formulation that addresses a defined bioavailability or stability problem.
• A patent covering a particular solid form or manufacturing intermediate.

Such claims must be evaluated against the Orange Book and relevant patent-family records. They do not automatically block a generic using the same excipient classes.

When does Eliquis lose exclusivity?

Eliquis lost FDA new chemical entity exclusivity in 2017. The relevant commercial barrier has since been the patent estate and associated generic litigation.

The principal timeline is:

Event	Date or status
FDA approval of Eliquis	December 28, 2012
Five-year NCE exclusivity	Expired in 2017
Core compound patent	Extended by pediatric exclusivity into late 2026
Generic litigation settlements	Reached with multiple ANDA applicants
Broad U.S. generic entry under reported settlements	Expected no earlier than April 1, 2028, subject to settlement terms and legal developments
Biosimilar pathway	Not applicable because apixaban is a small molecule

The settlement-based entry date is commercially more important than the nominal expiration date of the core patent for many generic applicants. Settlement agreements can permit entry before all listed patents expire, subject to agreed launch conditions.

Which companies are challenging Eliquis patents?

Multiple generic manufacturers have filed or pursued ANDAs for apixaban. Publicly reported litigation and settlement activity has involved companies including Teva Pharmaceuticals, Mylan, Hetero, Sigmapharm, and other generic applicants.[4]

The typical Paragraph IV strategy challenges one or more listed patents on grounds that the patent is invalid, unenforceable, or not infringed. A first-filer may seek 180-day generic exclusivity, although settlement structure, eligibility, forfeiture rules, and the identity of the qualifying applicant must be assessed from the actual FDA and court records.

What does a Paragraph IV challenge mean for commercial entry?

A Paragraph IV certification is an ANDA applicant’s assertion that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The certification can trigger patent litigation. A lawsuit filed within the statutory period can impose a 30-month stay of FDA approval, subject to statutory exceptions and court developments.[5]

For Eliquis, the commercial question is not whether generic applicants exist. It is whether a particular applicant has an enforceable right to launch before the settlement date or after the relevant stay and patent barriers expire.

What is the FDA regulatory status of Eliquis?

Eliquis is an FDA-approved prescription drug and is regulated as a small-molecule product. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.

The relevant regulatory controls include:

• Pharmaceutical equivalence.
• Bioequivalence.
• Same active ingredient, strength, dosage form, and route of administration.
• Manufacturing compliance with current good manufacturing practice.
• Stability and impurity control.
• Labeling consistent with the reference listed drug, subject to permitted differences.
• Pharmacovigilance for bleeding risk and other known safety issues.

An excipient change in a generic product can require additional development work even when the change is pharmaceutically conventional. The applicant must show that the altered formulation does not affect product performance or bioequivalence.

What generic launch risks exist for Eliquis?

Generic launch risk is concentrated in five areas.

Patent and settlement risk

A company may have an approved ANDA but remain unable to launch because of a settlement restriction, patent injunction, or contractual limitation.

Manufacturing scale risk

Eliquis is a high-volume product. A manufacturer must reliably produce both strengths, maintain coating color consistency, and meet supply commitments across multiple markets.

Low-dose content uniformity

The 2.5-mg product creates a higher risk of blend variability and batch failure than a higher-dose tablet with the same excipient platform.

Dissolution variability

Changes in sodium lauryl sulfate, croscarmellose sodium, lubricant blending, or apixaban particle size can produce clinically relevant dissolution differences.

Market-price compression

Several approved or launch-ready generic competitors could reduce prices rapidly after entry. The best margins are likely to accrue to early entrants, low-cost producers, and manufacturers with dependable supply rather than to late entrants with undifferentiated formulations.

How does Eliquis compare with competing anticoagulants?

Eliquis competes with rivaroxaban, dabigatran, edoxaban, and warfarin. Its excipient opportunity is distinctive because it is an immediate-release tablet with a conventional composition.

Product	Active ingredient	Dosage form	Generic or biosimilar pathway	Excipient opportunity
Eliquis	Apixaban	Immediate-release film-coated tablet	ANDA	High-volume conventional tablet platform
Xarelto	Rivaroxaban	Immediate-release tablet	ANDA	Formulation and dose-specific manufacturing
Pradaxa	Dabigatran etexilate	Capsule	ANDA	Capsule shell and moisture-control requirements
Savaysa	Edoxaban	Immediate-release tablet	ANDA	Smaller commercial base than Eliquis
Coumadin	Warfarin	Tablet	ANDA	Mature generic market with lower brand dependence

Eliquis has greater scale than several competing direct oral anticoagulants. That scale increases the value of supplier qualification, capacity reservations, and cost-efficient manufacturing.

What licensing and partnership opportunities exist?

The core commercial relationship is the Bristol Myers Squibb-Pfizer alliance for Eliquis commercialization. That relationship is distinct from excipient licensing. Excipient companies are more likely to pursue supply, formulation, or CDMO agreements than rights to the Eliquis brand or apixaban patent estate.

Potential deal structures include:

• Long-term excipient supply agreements.
• Dual-source qualification contracts.
• Technology-transfer agreements for film coating.
• Generic formulation-development partnerships.
• Regional licensing of approved or near-approved ANDAs.
• Authorized-generic supply arrangements.
• Contract manufacturing agreements tied to launch capacity.
• Analytical and stability-service agreements.

An excipient supplier with a proprietary high-performance grade may obtain commercial leverage through qualification barriers, but that leverage is operational rather than patent-based. Once a supplier’s material is embedded in an approved commercial process, switching can require comparability work, validation, stability data, and regulatory submissions.

What manufacturing and IP barriers affect Eliquis competition?

The main manufacturing barrier is process reproducibility. The formulation is technically accessible, but commercial-scale execution requires control of:

• Apixaban particle-size distribution.
• Blend segregation.
• Compression force and tablet tensile strength.
• Lubricant exposure time.
• Coating uniformity.
• Pigment dispersion.
• Dissolution across multiple production lots.
• Packaging and moisture protection.
• Supply continuity for pharmaceutical-grade excipients.

The main IP barrier is the remaining patent and settlement framework, not the excipient platform. A generic applicant that avoids a valid formulation claim through a non-infringing composition may still face bioequivalence and scale-up challenges.

What is the revenue exposure from Eliquis generic entry?

Eliquis is one of the largest products in the Bristol Myers Squibb and Pfizer portfolios. Generic entry is expected to create substantial price and volume pressure after launch, with the magnitude depending on the number of entrants, payer substitution, settlement terms, and the speed of formulary conversion.

Revenue exposure is likely to develop in stages:

1. Limited erosion while patent or settlement restrictions remain.
2. Rapid price reductions after the first commercial generic launches.
3. Accelerated erosion as additional ANDA holders enter.
4. Continued residual branded demand from prescribing habits, coverage preferences, and international market differences.

The excipient market benefits from increased unit volumes even as branded product revenue declines. Generic competition can therefore transfer value from the innovator to API manufacturers, excipient suppliers, tablet manufacturers, packagers, wholesalers, and payers.

What geographic opportunities exist for Eliquis excipients?

The United States is the highest-value near-term generic market because of Eliquis sales scale and ANDA competition. Europe and other regulated markets offer separate opportunities based on national patent status, regulatory approval, reimbursement, and local manufacturing requirements.

Excipient suppliers should prioritize:

• United States: ANDA and commercial-scale supply.
• European Union: centralized or national generic approvals and excipient compliance.
• Japan: local development and regulatory expectations.
• Canada and Australia: abbreviated regulatory pathways and payer substitution.
• Emerging markets: lower-cost formulations and regional manufacturing.

A global supplier with FDA, EMA, and other major-market documentation has an advantage over a lower-cost supplier that lacks regulatory support.

Key Takeaways

• Eliquis uses a conventional immediate-release film-coated tablet formulation.
• The main excipients are anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, hypromellose, triacetin, titanium dioxide, and iron oxides.
• The strongest excipient opportunities involve consistency, dual sourcing, regulatory support, and scale rather than standalone excipient patents.
• Low-dose content uniformity and dissolution control are the principal formulation challenges.
• Eliquis is subject to small-molecule ANDA competition, not biosimilar competition.
• Generic entry is constrained by the remaining patent estate and reported settlements, with broad U.S. entry expected no earlier than April 1, 2028 under those arrangements.
• Commercial value is likely to shift from the branded product to generic manufacturers, API and excipient suppliers, CDMOs, and packaging providers.
• The most defensible supplier position is qualification-based: validated performance, reliable capacity, multi-market documentation, and low switching risk.

FAQs

Does Eliquis contain sodium lauryl sulfate?

Yes. Sodium lauryl sulfate is listed as an inactive ingredient in Eliquis tablets and functions primarily as a wetting and dissolution aid.[1]

Can a generic apixaban use different excipients from Eliquis?

Yes. An ANDA may use different inactive ingredients if the product meets applicable regulatory requirements and demonstrates pharmaceutical equivalence, bioequivalence, quality, and safety.

Is apixaban a biologic requiring a biosimilar application?

No. Apixaban is a chemically synthesized small molecule. Generic versions use the ANDA pathway rather than the 351(k) biosimilar pathway.

Which Eliquis excipient is most important for dissolution?

Sodium lauryl sulfate, croscarmellose sodium, apixaban particle size, and magnesium stearate processing can all affect dissolution. No single excipient determines performance independently of the manufacturing process.

Can an excipient supplier patent a generic Eliquis formulation?

Potentially, but protection would generally require a novel and non-obvious composition, process, or performance feature. The common excipients used in Eliquis are themselves established materials and do not provide meaningful standalone exclusivity.

References

1. Bristol Myers Squibb and Pfizer. (2024). Eliquis (apixaban) prescribing information. U.S. Food and Drug Administration.

2. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 6,967,208: Compounds which are inhibitors of factor Xa. U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Bristol Myers Squibb. (2021). Bristol Myers Squibb and Pfizer announce settlement agreements resolving U.S. Eliquis patent litigation. Company investor and legal disclosure materials.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certification requirements. FDA.